Integral Diagnostics

Integral Diagnostics EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Integral Diagnostics (IDX.AX) as of Sep 21, 2026 is 67.65 M AUD. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was 114.07 M AUD — a change of -40.69% (lower).

EBITDA

67.65 MAUD

YoY

-40.69%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Integral Diagnostics is 2026 67.65 M AUD. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Integral Diagnostics was 2025 114.07 M AUD. It decreases by -40.69% lower compared to the previous year.

The Integral Diagnostics EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2019
51.38 M AUD
Jan 1, 2020
64.08 M AUD
Jan 1, 2021
82.79 M AUD
Jan 1, 2022
75.15 M AUD
Jan 1, 2023
83.62 M AUD
Jan 1, 2024
89.03 M AUD
Jan 1, 2025
114.07 M AUD
Jan 1, 2026
67.65 M AUD
The Integral Diagnostics EBITDA history
YEAREBITDAYoY
67.65 MAUD-40.69%
114.07 MAUD+28.12%
89.03 MAUD+6.47%
83.62 MAUD+11.28%
75.15 MAUD-9.23%
82.79 MAUD+29.18%
64.08 MAUD+24.72%
51.38 MAUD+34.96%
38.07 MAUD+13.58%
33.52 MAUD-4.85%
35.23 MAUD+4.60%
33.68 MAUD+396.79%
6.78 MAUD
Access this data via the Eulerpool API

Integral Diagnostics Stock analysis

What does Integral Diagnostics do? Integral Diagnostics Ltd is an Australian company that has been providing medical imaging services for over 25 years. The company was founded in 1994 by Dr. Ian Kadish and a team of radiologists in Perth, Western Australia, offering radiology services to local clinics and hospitals. Over the years, Integral Diagnostics has expanded its services to provide imaging services nationwide. The business model of Integral Diagnostics is to deliver medical imaging to enable doctors and their patients to have a fast and accurate diagnosis. The company offers imaging services for a variety of medical specialties, including radiology, cardiology, obstetrics and gynecology, and neurology. They operate over 49 locations in Australia, many of which are in rural areas where access to medical care may be limited. Integral Diagnostics offers a wide range of products based on medical imaging. These include X-rays, mammography, ultrasound, CT scans, MRI scans, PET scans, and bone density scans. The company takes pride in being one of the few Australian medical imaging companies to offer a complete range of imaging services. Their services are conducted by qualified radiologists specialized in interpreting medical images. Integral Diagnostics also operates clinics for performing diagnostic and therapeutic procedures such as biopsies, drainages, and injections. These procedures are carried out by highly qualified radiologists to provide patients with faster and more accurate diagnoses. Integral Diagnostics is committed to quality assurance and has a comprehensive quality management system that is annually reviewed by independent auditors. The company is accredited by both the Australian Medical Association and the Australian National Accreditation Scheme (NATA). These accreditations recognize the high standards that Integral Diagnostics sets for delivering medical imaging services. One of Integral Diagnostics' recent activities is their use of artificial intelligence (AI) in image interpretation. The company has partnered with MaxQ AI, a leading provider of AI solutions for medical imaging. Through this partnership, Integral Diagnostics doctors can utilize the latest AI tools to improve their patients' diagnoses. Integral Diagnostics is a strong advocate for social justice and is dedicated to supporting disadvantaged communities in Australia. The company has partnered with nonprofit organizations such as the National Breast Cancer Foundation, The Smith Family, and the Friendship Foundation. Overall, Integral Diagnostics has undergone impressive growth over the past 25 years and is now a leading Australian medical imaging company. With a wide range of imaging services and a strong focus on quality and social responsibility, the company is well-positioned to continue its success in the future. Integral Diagnostics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Integral Diagnostics stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Integral Diagnostics is 67.65 M AUD in 2026.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Integral Diagnostics changed from 114.07 M AUD to 67.65 M AUD, representing a -40.69% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) Integral Diagnostics since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s AUD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s Integral Diagnostics historically and in real time.

Access this data via the Eulerpool API

Income Statement — Integral Diagnostics

All Key Metrics — Integral Diagnostics